Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Luis Felipe Falla Zuñiga Armando Sardi Mary Caitlin King Mary Caitlin King Philipp Barakat Carol Nieroda Teresa P Diaz-Montes Vadim Gushchin

Published in: Pleura and peritoneum (2023)

In patients with PM from rare ovarian malignancies, CRS/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.

Keyphrases

minimally invasive
coronary artery bypass
particulate matter
air pollution
locally advanced
surgical site infection
double blind
acute coronary syndrome
newly diagnosed
metastatic renal cell carcinoma
percutaneous coronary intervention
chemotherapy induced